Factor VII Deficiency in an End-Stage Renal Disease Patient With Recurrent Thrombosis: A Case Report.

Autor: Shakhshir A; Department of Medicine, An-Najah National University Hospital, Nablus, PSE.; Internal Medicine, Al-Watani Hospital, Ministry of Health, Nablus, PSE., Dweekat M; Department of Internal Medicine, An-Najah National University Hospital, Nablus, PSE., Hamayel D; Department of Medicine, An-Najah National University Hospital, Nablus, PSE., Safarini OA; Department of Internships, Palestinian Ministry of Health, Nablus, PSE., Amer J; Department of Hematology, Faculty of Medicine and Health Sciences, An-Najah National University Hospital, Nablus, PSE., Enaya A; Department of Medicine, An-Najah National University Hospital, Nablus, PSE., Snober S; Department of Vascular Surgery, An-Najah National University Hospital, Nablus, PSE.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2023 Nov 09; Vol. 15 (11), pp. e48560. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
DOI: 10.7759/cureus.48560
Abstrakt: Congenital factor VII deficiency is a rare bleeding disorder with variable presentations. Thromboembolism is a well-established complication of this heterogeneous disease. As it is a rare disease, there is no information regarding its treatment when it is present with other comorbidities such as end-stage renal disease. This study describes a 47-year-old male with multiple comorbidities who was recently diagnosed with end-stage renal disease. He had recurrent admissions to the hospital due to thrombotic arteriovenous access failure as well as acute coronary syndrome, despite a high international normalized ratio that was resistant to replacement therapy. Eventually, apixaban became his main treatment regimen. This case needs to be reported because it is rare in terms of including a factor VII deficiency patient with end-stage renal disease, as well as to emphasize the unclear recommendations available for patients with factor VII deficiency and end-stage renal disease. International collaboration may be the best course of action to study enough patients and come up with effective recommendations.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Shakhshir et al.)
Databáze: MEDLINE